1125 GMT - Novo Nordisk is a "screaming buy," AlphaValue analyst Abhishek Raval writes. The company has a lead in the obesity market, a solid pipeline, aggressive intent toward licensing deals, and a valuation lower than both Novartis and AstraZeneca, he says. Underwhelming late-stage results from obesity candidate CagriSema, Trump tariff uncertainty, and concerns around a guidance downgrade due to competitive pressures have all weighed on Novo's share price. Nonetheless, AlphaValue has already baked some caution into 2025 estimates and still expects Novo's bottom line to register a 16% compound annual growth rate, which would be the highest among European big pharma over 2024-2027. AlphaValue lowers its target price on the stock to 943 Danish kroner from 981 kroner and retains its buy rating. Shares fall 2.4% to 467.75 kroner. (dominic.chopping@wsj.com)
(END) Dow Jones Newswires
April 02, 2025 07:25 ET (11:25 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。